Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
Walter Reinisch(Medical University of Vienna), Colleen Marano(Johnson & Johnson (United States)), Jean‐Frédéric Colombel(Mount Sinai Hospital), Dino Tarabar(Military Medical Academy), William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Lakshmi Padgett(Janssen (United States)), Paul Rutgeerts(KU Leuven), Judith Collins(Oregon Health & Science University), Richard Strauß(Hennepin County Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Omoniyi J. Adedokun(Western University)
Cited by 35
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k